Japan's Leading Medical Services Organization for Longevity.
Japan's leading Medical Services Organization (MSO) — a structure familiar to healthcare investors — operating 284 clinics across 20+ brands. From a single clinic in Fujisawa in 2000 to 6.76 million customers today, and now expanding into the global Longevity market.
Nasdaq Listed Sep 2024
Symbol
Nasdaq : SBCPrice
$Volume
Change
Q1 FY2026 Key Figures
Locations
Customers (LTM)
Repeat Rate
EBITDA
EBITDA Margin
Basic EPS
Investment Highlights
Six reasons SBC is built to compound.
Japan's #1 Aesthetic Medical Group1
From a single clinic in 2000 to 284 locations across 20+ brands. 6.76M+ annual customers, 72% repeat rate. Clinic count and customer base have grown continuously for over 25 years.
Clinics
Customers
Brands
A Self-Reinforcing Competitive Moat
Exceptional service, network accessibility, overwhelming brand trust, high repeat rates, and large case volume reinforce each other in a flywheel that creates a barrier to replication.
Repeat Rate
Strong Profitability Recycled Into Growth
FY2025 Net income attributable to SBC of $51MM (+9% YoY). EBITDA Margin 40%+. Ample cash flow continuously recycled into growth investment, driving a self-sustaining growth engine.
FY25 Net Income
EBITDA Margin
Cash on B/S
First-Mover Advantage in Japan's Longevity Market
Uniquely positioned to address Longevity from both "appearance" (aesthetic medicine) and "physical wellness" (general medicine). No dominant leader yet established in Japan's early-stage market.
Replicating Our Japan Model Overseas
M&A and partnership-driven expansion across Southeast Asia and the U.S. Strategic minority investment in OrangeTwist enables MedSpa and Longevity business development.
Experienced Leadership Across Disciplines
Russell 3000® inclusion in 2025. A management team with deep expertise across finance, medicine, and global business, executing a disciplined growth strategy.
Structural Competitive Advantage
A Barrier to Replication Built Over 25 Years
Each element of SBC's competitive position strengthens the others. Exceptional service drives high repeat rates. High repeat rates fund network expansion. A larger network grows brand trust. Brand trust enables premium pricing and case volume — which in turn reinvests into service quality.
This flywheel is why a new entrant cannot replicate SBC's position by simply copying any single element. They would need to replicate the entire system simultaneously — and earn 25 years of customer trust.
FOUNDATIONAL CAPABILITIES POWERING THE FLYWHEEL
Data-Based Management
Strategies leveraging vast customer & case data
Academic Activities
75 doctors as speakers, 28 conferences in FY2025
Integrated Infrastructure
Comprehensive, fast, and low-cost service delivery
Advanced HR Education
Training and manuals ensuring consistent quality
Strategic Vision
A youthful, vital life — through Longevity.
Approaching both appearance and physical wellness is key to living a youthful, vital life. SBC will leverage all its
capabilities to address the Longevity market through four integrated growth strategies.
Aesthetic
Appearance-Based Approach
Longevity
A Youthful, Vital Life
Non-Aesthetic
Physical Wellness Approach
Multi-Brand Strategy in Aesthetic Dermatology
Maximize market share through targeted brand portfolio across SBC, Rize, Gorilla, AHH, and JUN brands.
Non-Aesthetic Business Expansion
Apply aesthetic healthcare expertise to diversify into orthopedics, dentistry, fertility, ophthalmology, and AGA.
Global Business Expansion
Expand aesthetic dermatology clinics to the U.S. and Southeast Asia through M&A and strategic partnerships.
AI-Driven Competitiveness & Cost Reform
Transform clinical and operational data into AI learning resources to build proprietary competitive advantages.
Latest Results
Q1 FY2026 · Quarter Ended March 31, 2026
Stay Informed
Get SBC investor updates delivered.
Be the first to receive earnings releases, SEC filings, strategic announcements, and event invitations directly to your inbox. Subscribe by topic — no spam, no marketing.
Contact Us
For inquiries from institutional investors, sell-side analysts, and shareholders, please reach out directly to our Investor Relations team. We typically respond within one business day (JST).
HQ — Americas
Head of Investor Relations
[email protected]
Media Contact
Corporate Communications
[email protected]
HQ — Americas
United States
HQ — Japan
Shinjuku-ku, Tokyo